Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Patrick Oeckl; Steffen Halbgebauer; Sarah Anderl-Straub; Petra Steinacker; Andre M. Hussa; Hermann Neugebauer; Christine A.F. Von Arnim; Janine Diehl-Schmid; Timo Grimmer; Johannes Kornhuber; Piotr Lewczuk; Adrian Danek; Lobar Degeneration; Albert C. Ludolph; Markus Otto

doi:10.3233/JAD-180325

Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Patrick Oeckl
, Steffen Halbgebauer
, Sarah Anderl-Straub
, Petra Steinacker
, Andre M. Hussa
, Hermann Neugebauer
, Christine A.F. Von Arnim
, Janine Diehl-Schmid
, Timo Grimmer
, Johannes Kornhuber
, Piotr Lewczuk
, Adrian Danek
, Lobar Degeneration
, Albert C. Ludolph
, Markus Otto

Department of Psychiatry and Psychotherapy

University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
Friedrich-Alexander Universitat Erlangen-Nurnberg (FAU)
Medical University of Bialystok
Ludwig-Maximilians-Universität München
University of Ulm

Research output: Contribution to journal › Article › peer-review

289 Scopus citations

Abstract

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

Original language	English
Pages (from-to)	481-488
Number of pages	8
Journal	Journal of Alzheimer's Disease
Volume	67
Issue number	2
DOIs	https://doi.org/10.3233/JAD-180325
State	Published - 2019

Keywords

Alzheimer's disease
GFAP
Lewy body dementia
Parkinson's disease
astrocyte
biomarker
cerebrospinal fluid
differential diagnosis
frontotemporal dementia
serum

Access to Document

10.3233/JAD-180325

Cite this

Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Hussa, A. M., Neugebauer, H., Von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., Lewczuk, P., Danek, A., Degeneration, L., Ludolph, A. C., & Otto, M. (2019). Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment. Journal of Alzheimer's Disease, 67(2), 481-488. https://doi.org/10.3233/JAD-180325

@article{9e44a9de866042d6991e43e943e40c01,

title = "Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment",

abstract = "Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89\% and 79\% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.",

keywords = "Alzheimer's disease, GFAP, Lewy body dementia, Parkinson's disease, astrocyte, biomarker, cerebrospinal fluid, differential diagnosis, frontotemporal dementia, serum",

author = "Patrick Oeckl and Steffen Halbgebauer and Sarah Anderl-Straub and Petra Steinacker and Hussa, \{Andre M.\} and Hermann Neugebauer and \{Von Arnim\}, \{Christine A.F.\} and Janine Diehl-Schmid and Timo Grimmer and Johannes Kornhuber and Piotr Lewczuk and Adrian Danek and Lobar Degeneration and Ludolph, \{Albert C.\} and Markus Otto",

year = "2019",

doi = "10.3233/JAD-180325",

language = "English",

volume = "67",

pages = "481--488",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "SAGE Publications Ltd",

number = "2",

}

Oeckl, P, Halbgebauer, S, Anderl-Straub, S, Steinacker, P, Hussa, AM, Neugebauer, H, Von Arnim, CAF, Diehl-Schmid, J , Grimmer, T, Kornhuber, J, Lewczuk, P, Danek, A, Degeneration, L, Ludolph, AC & Otto, M 2019, 'Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment', Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 481-488. https://doi.org/10.3233/JAD-180325

TY - JOUR

T1 - Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

AU - Oeckl, Patrick

AU - Halbgebauer, Steffen

AU - Anderl-Straub, Sarah

AU - Steinacker, Petra

AU - Hussa, Andre M.

AU - Neugebauer, Hermann

AU - Von Arnim, Christine A.F.

AU - Diehl-Schmid, Janine

AU - Grimmer, Timo

AU - Kornhuber, Johannes

AU - Lewczuk, Piotr

AU - Danek, Adrian

AU - Degeneration, Lobar

AU - Ludolph, Albert C.

AU - Otto, Markus

PY - 2019

Y1 - 2019

N2 - Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

AB - Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

KW - Alzheimer's disease

KW - GFAP

KW - Lewy body dementia

KW - Parkinson's disease

KW - astrocyte

KW - biomarker

KW - cerebrospinal fluid

KW - differential diagnosis

KW - frontotemporal dementia

KW - serum

UR - https://www.scopus.com/pages/publications/85060574339

U2 - 10.3233/JAD-180325

DO - 10.3233/JAD-180325

M3 - Article

C2 - 30594925

AN - SCOPUS:85060574339

SN - 1387-2877

VL - 67

SP - 481

EP - 488

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 2

ER -

Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this